Fig. 1

Results of the primary screen of the Medicines for Malaria Venture (MMV) Global Health Priority Box (n = 240) against (A) exsheathed third-stage larvae (xL3s) of Haemonchus contortus and (B) young adults of Caenorhabditis elegans with reference to four distinct control compounds (monepantel, monepantel/abamectin, M-666 and moxidectin) and a negative (LB* + 1% DMSO) control. All test and positive-control compounds were tested at 20 μM. Each grey dot represents an individual test compound. Mean ± standard error of the mean (SEM) indicated for positive-control compounds (four data points) and negative controls (32 data points for LB* + 1% DMSO). For all screens, the Z′ factor ranged between 0.76 and 0.92